De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer

被引：0
|
作者：
Lorena Gonzalez
Joanne Mortimer
Laura Kruper
机构：
[1] City of Hope National Medical Center,Department of Surgery, Division of Breast Surgery
[2] City of Hope National Medical Center,Department of Medical Oncology
来源：
Current Breast Cancer Reports | 2021年 / 13卷
关键词：
Systemic chemotherapy; Her2+ breast cancer; Triple-negative breast cancer; T1a,bN0;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：151 / 156
页数：5
相关论文
共 50 条
  • [31] The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer
    Wolfe, Emily
    Corsetti, Ralph
    Bolton, John S.
    Stolier, Alan J.
    Fuhrman, George M.
    AMERICAN JOURNAL OF SURGERY, 2013, 206 (06): : 888 - 892
  • [32] Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
    Nederlof, Iris
    Voorwerk, Leonie
    Kok, Marleen
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2362 - 2370
  • [33] National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial
    Christine Rogers
    Adrienne N. Cobb
    Jan I. C. Lloren
    Lubna N. Chaudhary
    Morgan K. Johnson
    Chiang-Ching Huang
    Mediget Teshome
    Amanda L. Kong
    Puneet Singh
    Chandler S. Cortina
    Breast Cancer Research and Treatment, 2024, 203 : 317 - 328
  • [34] National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial
    Rogers, Christine
    Cobb, Adrienne N.
    Lloren, Jan I. C.
    Chaudhary, Lubna N.
    Johnson, Morgan K.
    Huang, Chiang-Ching
    Teshome, Mediget
    Kong, Amanda L.
    Singh, Puneet
    Cortina, Chandler S.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 317 - 328
  • [35] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [36] The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer: A Review
    Anders, Carey K.
    Zagar, Timothy M.
    Carey, Lisa A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (04) : 737 - +
  • [37] Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer.
    Ovcaricek, Tanja
    Matos, Erika
    Auprih, Masa
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
    Maltoni, Roberta
    Palleschi, Michela
    Altini, Mattia
    Massa, Ilaria
    Balzi, William
    Ravaioli, Sara
    Tumedei, Maria Maddalena
    Rocca, Andrea
    Bravaccini, Sara
    CLINICAL BREAST CANCER, 2020, 20 (04) : 359 - 360
  • [39] Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer
    Gandhi, Shipra
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [40] Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
    Gorshein, Elan
    Klein, Paula
    Boolbol, Susan K.
    Shao, Theresa
    CLINICAL BREAST CANCER, 2014, 14 (05) : 309 - 314
12345